BMS 833923

Drug Profile

BMS 833923

Alternative Names: BMS-833923; XL-139

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Exelixis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Hedgehog cell-signalling pathway inhibitors; SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic myeloid leukaemia
  • No development reported Gastrointestinal cancer; Multiple myeloma; Small cell lung cancer; Solid tumours

Most Recent Events

  • 01 Jan 2017 Bristol-Myers Squibb terminates a phase II trial as no participants enrolled in this trial could receive the recommended phase 2 dose in Chronic myeloid leukaemia (Newly diagnosed, First-line therapy, Combination therapy) in USA, Argentina, Belgium, Canada, Finland, France, Germany, Poland and Spain (NCT01357655)
  • 15 Dec 2016 Biomarkers information updated
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in Canada (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top